REFERENCES
- Vardanian AJ, Busuttil RW, Kupiec-Weglinski JW. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med. 2008;14:337–345.
- de Rougemont O, Lehmann K, Clavien PA. Preconditioning, organ preservation, and postconditioning to prevent ischemia–reperfusion injury to the liver. Liver Transpl. 2009;15:1172–1182.
- Sindram D, Rüdiger HA, Upadhya AG, Ischemic preconditioning protects against coldischemic injury through an oxidative stres dependent mechanism. J Hepatol. 2002;36:78–84.
- Clavien PA, Yadav S, Sindram D, Protective effects of ischemic preconditioning for liver resection performed render in for occlusion in humans. Am Surg. 2000; 232:155.
- Romero Valdés A, Menéndez Cepero S, Gómez Moraleda M, Ozone therapy in the advanced stages of arteriosclerosis obliterans. Angiologia. 1993;45:146–148.
- Menendez S, Iglesias O, Bidot C. Application of ozone in children with humoral immunity deficiency. In: Proceedings of the 12th Ozone World Congress Ozone in Medicine. Lille: Int Ozone Assoc. 1995;271–274.
- Hernandez F, Menendez S, Wong R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Rad Biol Med. 1995;19:115–119.
- León OS, Menéndez S, Merino N, Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediat Inflamm. 1998;7:289–294.
- Candelario-Jalil E, Mohammed-Al-Dalain S, Fernández OS, Oxidative preconditioning affords protection against carbontetrachloride-induced glycogen depletion and oxidative stress in rats. J Appl Toxicol. 2001;21:297–301.
- Al-Dalain SM, Martínez G, Candelario-Jalil E, Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Pharmacol Res. 2001;44:391–396.
- Ajamieh H, Merino N, Candelario-Jalil E, Similar protective effect of ischaemia and oxidative preconditioning in liver ischaemic/reperfusion injury. Pharmacol Res. 2002;45:333–339.
- Bocci VA. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res. 2006;37:425–435.
- Bocci V. Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Med Hypotheses. 1996;46:150–154.
- Jaeschke H, Woolbright BL. Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species. Transplant Rev (Orlando). 2012;26:103–114.
- Ajamieh HH, Menéndez S, Martínez-Sánchez G, Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia-reperfusion. Liver Int. 2004;24:55–62.
- Ajamieh HH, Berlanga J, Merino N, Role of protein synthesis in the protection conferred by ozone-oxidative-preconditioning in hepatic ischaemia/reperfusion. Transpl Int. 2005;18:604–612.
- Arai M, Thurman RG, Lemasters JJ. Contribution of adenosine A (2) receptors and cyclic adenosine monophosphate to protective ischemic preconditioning of sinusoidal endothelial cells against storage/reperfusion injury in rat livers. Hepatology. 2000;32:297.
- Kume M, Yamamoto Y, Saad S, Ischemic preconditioning of the liver in rats: implications of heat shock protein induction to increase tolerance of ischemia-reperfusion injury. J Lab Clin Med. 1996;128:251.
- LeónFernández OS, Ajamieh HH, Berlanga J, Ozone oxidative preconditioning is mediated by A1 adenosine receptors in a rat model of liver ischemia/reperfusion. Transpl Int. 2008;21:39–48.
- Perry BC, Soltys D, Toledo AH, Tumor necrosis factor-α in liver ischemia/reperfusion injury. J Invest Surg. 2011;24:178–188.
- Ikejima K, Qu W, Stachlewitz RF, Kupffer cells contain a glycine-gated chloride channel. Am J Physiol Gastrointest Liver Physiol. 1997;272:G1581–G1586.
- Webber EM, Bruix J, Pierce RH, Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology. 1998;28:1226–1234.
- Selzner N, Selzner M, Tian Y, Cold ischemia decreases liver regeneration after partial liver transplantation in the rat: a TNF-alpha/IL-6-dependent mechanism. Hepatology. 2002;36:812–818.
- Yamada Y, Kirillova I, Peschon JJ, Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA. 1997;94:1441–1446.
- Yamada Y, Webber EM, Kirillova I, Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology. 1998;28:959–970.
- Cressman D, Greenbaum L, DeAngelis R, Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274:1379–1383.
- Campbell JS, Prichard L, Schaper F, Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest. 2001;107:1285–1292.
- Webber EM, Bruix J, Pierce RH, Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology. 1998;28:1226–1234.
- Cressman DE, Greenbaum LE, Haber B, Rapid activation of post-hepatectomy factor/nuclear factor B in hepatocytes, a primary responsein the regenerating liver. J BiolChem. 1994;269:30429–30435.
- Chae HJ, Chae SW, Chin HY, The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts. Bone. 2001;28:45–53.
- Taub R. Hepatoprotection via the IL-6/STAT3 pathway. J Clin Invest. 2003;112:978–980.
- Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19:2548–2556.
- Selzner M, Camargo C, Clavien PA. Ischemia impairs liver regeneration following major tissue loss in the rodent. Hepatology. 1999;30:469–475.
- Selzner M, Clavien PA. Failure of regeneration of the steatotic rat liver disruption at two different levels of the regenration pathway. Hepatology. 2000;31:35–42.
- Teoh N, Field J, Farrell G. Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice. J Hepatol. 2006;45:20–27.
- Latanich CA, Toledo-Pereyra LH. Searching for NF-kappaB-based treatments of ischemia reperfusion injury. J Invest Surg. 2009;22:301–315.
- Luedde T, Trautwein C. Intracellular survival pathways in the liver. Liver Int. 2006;26:1163–1174.
- Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol. 2006;290:583–589.
- Kuboki S, Okaya T, Schuster R, Hepatocyte NF-kappaB activation is hepatoprotective during ischemia-reperfusion injury and is augmented by ischemic hypothermia. Am J Physiol. 2007;292:201–207.
- Suetsugu H, Limuro Y, Uehara T, Nuclear factor {kappa}B inactivation in the rat liver ameliorates short term total warm ischaemia/reperfusion injury. Gut. 2005;54:835–842.
- Luedde T, Assmus U, Wüstefeld T, Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest. 2005;115:849–859.
- Beraza N, Lüdde T, Assmus U, Hepatocyte specific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology. 2007;132:2504–2517.
- Lou H, Kaplowitz N. Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-kappaB activity via IkappaB kinase-dependent and -independent mechanisms. J Biol Chem. 2007;282:29470–29481.
- Dröge W, Schulze-Osthoff K, Mihm S, Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J. 1994;8:1131–1138.
- Llacuna L, Marí M, Lluis JM, Reactive oxygen species mediate liver injury through parenchymal nuclear factor-kappaB inactivation in prolonged ischemia/reperfusion. Am J Pathol. 2009;174:1776–1785.